

OUR PIPELINE

LAST UPDATED: JANUARY 9, 2025

We are building a pipeline of *in vivo* and *ex vivo* therapies, as well as continuing to develop innovative modular platform capabilities.

IN VIVO PROGRAMS

IN VIVO CRISPR **is** the therapy
GENETIC DISEASES

PROGRAM	APPROACH	RESEARCH AND PRECLINICAL	EARLY-STAGE CLINICAL	LATE-STAGE CLINICAL	PARTNERS
NTLA-2002 Hereditary Angioedema	Knockout				 LEAD
Nex-z* Transthyretin Amyloidosis	Knockout				 LEAD REGENERON
Hemophilia A / B***	Insertion				 LEAD REGENERON
Research Programs for Extra-hepatic Targets	Various				** ReCode REGENERON SPARINGVISION

EX VIVO PROGRAMS

EX VIVO CRISPR **creates** the therapy
IMMUNO-ONCOLOGY / AUTOIMMUNE DISEASE

PROGRAM	APPROACH	RESEARCH AND PRECLINICAL	EARLY-STAGE CLINICAL	LATE-STAGE CLINICAL	PARTNERS
Research Programs	Allogeneic and other				** kyverna AVENCELL ONK THERAPEUTICS

AATD: Alpha-1 Antitrypsin Deficiency

Lead refers to lead development and commercial party.

* Intellia is advancing both wholly-owned and partnered programs.

** Nex-z (nexiguran ziclumeran), formerly known as NTLA-2001.

*** Hemophilia A program is in the research stage. Hemophilia B is being advanced by Regeneron. Intellia is eligible for milestones and royalties.